Bluebird’s regulatory chief departs two days after historic gene therapy nod to join Flagship’s Tessera
Just two days after securing FDA approval for the first gene therapy for a chronic condition, bluebird bio’s chief regulatory officer was on to her next journey.
After an 11-year career at bluebird, Anne-Virginie Eggimann has moved over to Tessera Therapeutics, the Flagship-incubated biotech that recently attracted former AbbVie vice chair Michael Severino as CEO. She’ll hold the same post at her new employer, which is attempting to create the field of “gene writing.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.